52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Ppd Reports Q1 EPS $0.21
Thermo Fisher Nears Deal To Buy PPD For More Than $15 Billion- WSJ
Ppd Posts Q4 Adjusted Earnings Per Share $0.39
PPD, Inc. provides drug development services to the biopharmaceutical industry. The Company provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations, as well as other industry participants. The Company’s business segments include Clinical Development Services segment and Laboratory Services segment. Its Clinical Development Services offerings span the lifecycle of clinical product development and includes product development and consulting services, early development services, phases II-IV clinical trial management, accelerated enrollment solutions, peri- and post-approval services and medical communications. The Company’s Laboratory Services segment offers bioanalytical laboratory services, biomarker laboratory services, vaccine science services, good manufacturing practice (GMP) laboratory services and central laboratory services.
Biotechnology & Drugs
929 North Front Street
David S. Simmons
Chairman of the Board, Chief Executive Officer
Christopher G. Scully
Chief Financial Officer, Executive Vice President, Treasurer, Assistant Secretary
William J. Sharbaugh
Chief Operating Officer
Ronald E. Garrow
Chief Human Resource Officer, Executive Vice President
B. Judd Hartman
Executive Vice President, Chief Administrative Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Medical device maker Thermo Fisher Scientific Inc said on Thursday it would acquire contract researcher PPD Inc for $17.4 billion as it looks to add more muscle to its pharmaceutical services business.
Cravath, Swaine & Moore and Arnold & Porter Kaye Scholer are guiding medical device maker Thermo Fisher Scientific Inc in its $17.4 billion cash acquisition of drug testing company PPD Inc, which turned to Simpson, Thacher & Bartlett.
Thermo Fisher Scientific Inc on Thursday said it would acquire contract research firm PPD Inc for about $20.9 billion, including net debt. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Bernard Orr)
Medical device company Thermo Fisher Scientific is nearing a deal to buy contract research firm PPD Inc for more than $15 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Thermo Fisher Scientific is nearing a deal to buy PPD Inc for more than $15 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
* PPD EXPANDS LABORATORY TEST PORTFOLIO FOR COVID-19 THERAPY AND VACCINE DEVELOPMENT PROGRAMS Source text for Eikon: Further company coverage:
* PPD, INC. ANNOUNCES PRICING AND UPSIZING OF SENIOR NOTES OFFERING
* PPD INC - NOTES ARE EXPECTED TO BE ISSUED BY COMPANY'S INDIRECT WHOLLY OWNED SUBSIDIARIES, JAGUAR HOLDING COMPANY II AND PPD DEVELOPMENT, L.P.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.